Harae Dx Corp.

Harae Dx is a medical device company in Pleasanton, California, founded in 2021 by Sanjeev Saxena. Its pitch - and it is a big one - is that it has built one of the world's smallest portable, automated systems for early cancer detection. The first product is an early breast cancer test. The underlying chemistry is a panel of biomarkers the company exclusively licensed from Lawrence Livermore National Laboratory, which is a sentence worth pausing on, because Livermore is a place better known for supercomputers and nuclear stewardship than for blood tests. National labs generate an enormous amount of intellectual property they will never commercialize themselves. Occasionally a startup shows up and turns one of those licenses into a product. That is the origin story here.

The mechanism is called centrifugal microfluidics, sometimes marketed as a "lab-on-a-disc." You put a small blood sample onto a disc, the disc spins, and centrifugal force moves fluid through tiny channels to mix reagents, separate components, and run the assay - no pumps, no technician pipetting between steps, no courier. The company reports the system detects protein and genetic biomarkers associated with early breast cancer and returns a result in roughly 30 minutes, with reported performance of 85% sensitivity and 91% specificity. Those are the company's numbers, not an independent regulator's, and the honest framing is that a portable diagnostic lives or dies on clinical validation. But the strategic logic is clean: automate the whole assay, remove the human handoffs, and you remove both the wait and a category of processing error.

Why does portability matter so much? Because early detection is the entire game in cancer, and early detection only helps the people it actually reaches. A brilliant test that lives inside a central laboratory is useless to a clinic three hours away that never had one. Harae Dx's whole strategy - small, cheap, fast, self-contained - is aimed at that gap. It is a distribution argument dressed as a hardware argument, which is usually the correct way to think about medical devices.

The team is small - around six people - and notably not a group of strangers. Several core members, including VP of Engineering Ali Muckadam and India operations lead Dr. Nitin Malekar, previously worked with Saxena at POC Medical Systems, his prior portable-diagnostics company. Saxena describes a 30-year career building medical device and biotech companies and raising more than $70 million along the way. Repeat teams in hard tech are worth paying attention to, because the hardest part of shipping a portable diagnostic is not the idea - it is the thousand unglamorous integration problems, and a team that has solved them once tends to solve them faster the second time.

The money, so far, is early-stage and modest. Harae Dx raised a seed round in April 2021 from SOSV and its hard-tech accelerator HAX, and later disclosed additional funding with Fusion Fund joining. Disclosed totals sit around $350,000, which tells you this is a company still in the building phase rather than the scaling phase. HAX is a useful signal here: it specializes in de-risking capital-intensive hardware, and it does not typically fund software wrappers. A cancer-detection device is exactly the kind of physical, slow-to-mature bet it exists to support.

The roadmap is a platform play. Breast cancer is first because that is where the licensed panel points, but the stated ambition is to add tests for prostate, lung, cervical, colorectal and other cancers on the same instrument. That only works if the first test earns clinical and regulatory trust, which is the long, expensive part no press release can skip past. For now Harae Dx is what it is: a small team with a licensed biomarker panel, a spinning disc, and a coherent theory that cancer screening belongs closer to the patient than the central lab currently allows. Whether the numbers hold up under scrutiny is the question that decides everything - and it is a question only time and trials answer.